Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
22. Januar 2025 16:05 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
08. Januar 2025 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
19. Dezember 2024 08:00 ET
|
Alumis Inc.
In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers
04. Dezember 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Neurology Clinical Trials Market Size Is Expected To Reach a Revenue Of USD 9,231.1 Mn By 2033, at 5.8% CAGR: Dimension Market Research
25. November 2024 09:26 ET
|
Dimension Market Research
New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Neurology Clinical Trials Market size is expected to reach USD 5,549.3 million by 2024 and it is further anticipated to reach...
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
01. November 2024 13:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
26. September 2024 01:00 ET
|
PolTREG S.A.
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy...
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
19. September 2024 10:50 ET
|
Precede Biosciences, Inc.
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
16. September 2024 01:00 ET
|
PolTREG S.A.
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to...
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
22. August 2024 07:00 ET
|
Abata
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis